[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 16 of about 16
1. Sebastián Villalón-López J, Arturo Valle-Mejía C, Patiño-Lara A, Moreno-Pérez Bertha A, Alejo Muñoz-López J, Alcantar-Andrade A: Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review. J Cancer Res Ther; 2005 Jul-Sep;1(3):132-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supraestructure maxillectomy and orbital exenteration for treatment of basal cell carcinoma of inferior eyelid: case report and review.
  • Basal cell carcinoma (BCC) is the most frequent type of skin cancer in humans, with cumulative exposure to ultraviolet radiation (UVR) as important risk factor for development of the illness as such as severe solar burns during childhood or adolescence.
  • BCC is mainly located on sun exposed sites, being head and neck the areas of more incidence; although nose, eyelids and periorbitary tissue are unfavorable due to cosmetic results that BCC involves.
  • Several treatment options as surgical and non-surgical are available.
  • The goal of treatment is complete excision of the tumor with preservation of surrounding structures in a way aesthetically acceptable.
  • Mohs' micrographic surgery is the standard treatment for all non-melanoma skin cancer.
  • Orbital exenteration is also used for treatment of malignancies of ocular tissues, mainly squamous cell carcinoma, sebaceous cell carcinoma and BCC.
  • The tissue beneath the surgical site can be left for second-intention granulation or covered with a cutaneous implant of partial thickness.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Maxilla / surgery. Orbit Evisceration / methods
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / drug therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998643.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 15
  •  go-up   go-down


2. Luba MC, Bangs SA, Mohler AM, Stulberg DL: Common benign skin tumors. Am Fam Physician; 2003 Feb 15;67(4):729-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common benign skin tumors.
  • Benign skin tumors are commonly seen by family physicians.
  • Any lesions for which the diagnosis is uncertain, based on the history and gross examination, should be biopsied for histopathologic examination to rule out malignancy.
  • Lipomas are technically subcutaneous soft tissue tumors, not skin tumors, and controversy exists about whether keratoacanthomas have malignant potential; however, both are discussed in this article because they are common tumors evaluated by family physicians.
  • Diagnosis usually is based on the appearance of the lesion and the patient's clinical history, although biopsy is sometimes required.
  • Treatment includes excision, cryotherapy, curettage with or without electrodesiccation, and pharmacotherapy, and is based on the type of tumor and its location.
  • Generally, excision is the treatment of choice for lipomas, dermatofibromas, keratoacanthomas, pyogenic granulomas, and epidermoid cysts.
  • Cherry angiomas and sebaceous hyperplasia are often treated with laser therapy and electrodesiccation.
  • Common treatments for acrochordons and seborrheic keratoses are cryotherapy and shave excision.
  • Referral is indicated if the family physician is not confident with the diagnostic evaluation or treatment of a lesion, or if a biopsy reveals melanoma.
  • [MeSH-major] Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Minor Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613727.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


3. Schmidt A, Harada S, Kimmel DB, Bai C, Chen F, Rutledge SJ, Vogel RL, Scafonas A, Gentile MA, Nantermet PV, McElwee-Witmer S, Pennypacker B, Masarachia P, Sahoo SP, Kim Y, Meissner RS, Hartman GD, Duggan ME, Rodan GA, Towler DA, Ray WJ: Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J Biol Chem; 2009 Dec 25;284(52):36367-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands.
  • Androgen replacement therapy is a promising strategy for the treatment of frailty; however, androgens pose risks for unwanted effects including virilization and hypertrophy of reproductive organs.
  • Selective Androgen Receptor Modulators (SARMs) retain the anabolic properties of androgens in bone and muscle while having reduced effects in other tissues.
  • This gene-selective agonism manifests as tissue-selectivity: in ovariectomized rats, Cl-4AS-1 mimics DHT while TFM-4AS-1 promotes the accrual of bone and muscle mass while having reduced effects on reproductive organs and sebaceous glands.
  • To confirm that the biochemical properties of TFM-4AS-1 confer tissue selectivity, we identified a structurally unrelated compound, FTBU-1, with partial agonist activity coupled with antagonism of the N-terminal/C-terminal interaction and found that it also behaves as a SARM.
  • TFM-4AS-1 and FTBU-1 represent two new classes of SARMs and will allow for comparative studies aimed at understanding the biophysical and physiological basis of tissue-selective effects of nuclear receptor ligands.
  • [MeSH-minor] Animals. Antigens, Viral, Tumor / metabolism. Male. Promoter Regions, Genetic. Prostate / growth & development. Prostate / metabolism. Rats. Rats, Sprague-Dawley. Receptors, Androgen / metabolism. Viral Core Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Anabolic Steroids.
  • COS Scholar Universe. author profiles.
  • Nuclear Receptor Signaling Atlas (NURSA). supplemental materials - Curated dataset for this article .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. Nuclear Receptor Signaling Atlas: Data: Gene Expression .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 2000 Aug 1;39(30):8917-28 [10913304.001]
  • [Cites] Front Horm Res. 2009;37:74-90 [19011290.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):724-31 [11158037.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):923-35 [11376111.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2380-1 [11923515.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2185-93 [12727974.001]
  • [Cites] Ann Endocrinol (Paris). 2003 Apr;64(2):109-14 [12773944.001]
  • [Cites] Aging Male. 2003 Sep;6(3):166-74 [14628497.001]
  • [Cites] Front Horm Res. 2009;37:91-107 [19011291.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2003 Nov;58(11):1002-8 [14630881.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1310-22 [14576152.001]
  • [Cites] Drugs Aging. 2004;21(6):361-76 [15084139.001]
  • [Cites] Mol Endocrinol. 2004 Aug;18(8):1876-86 [15118070.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):247-57 [15336702.001]
  • [Cites] Cell. 1990 Sep 21;62(6):1205-15 [2169352.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):778-84 [1428232.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1634-41 [1333051.001]
  • [Cites] Endocr Rev. 1993 Oct;14(5):651-8 [8262011.001]
  • [Cites] Calcif Tissue Int. 1993 Oct;53(4):278-82 [8275357.001]
  • [Cites] Eur J Cancer. 1994;30A(4):484-90 [8018407.001]
  • [Cites] Mol Endocrinol. 1995 Aug;9(8):1017-28 [7476976.001]
  • [Cites] Mol Endocrinol. 1995 Jun;9(6):659-69 [8592512.001]
  • [Cites] J Biol Chem. 1996 Sep 27;271(39):23907-13 [8798622.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Mar;60(5-6):303-9 [9219921.001]
  • [Cites] Science. 1997 Sep 5;277(5331):1508-10 [9278514.001]
  • [Cites] J Biol Chem. 1998 Jan 2;273(1):92-101 [9417052.001]
  • [Cites] Endocrinology. 1998 Mar;139(3):1411-9 [9492078.001]
  • [Cites] Curr Opin Chem Biol. 1998 Aug;2(4):508-11 [9736924.001]
  • [Cites] Am J Obstet Gynecol. 1999 Mar;180(3 Pt 2):S308-11 [10076169.001]
  • [Cites] Mech Ageing Dev. 2004 Oct-Nov;125(10-11):683-95 [15541764.001]
  • [Cites] Endocrinology. 2005 Feb;146(2):564-78 [15498879.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2005 Sep;113(8):457-63 [16151980.001]
  • [Cites] J Biol Chem. 2005 Nov 25;280(47):38898-901 [16166078.001]
  • [Cites] J Endocrinol Invest. 2005;28(10 Suppl):73-9 [16550728.001]
  • [Cites] J Mol Endocrinol. 2006 Apr;36(2):361-8 [16595706.001]
  • [Cites] Eur J Endocrinol. 2006 Dec;155(6):773-81 [17132744.001]
  • [Cites] Pharm Res. 2006 Aug;23(8):1641-58 [16841196.001]
  • [Cites] Drug Discov Today. 2007 Mar;12(5-6):241-8 [17331889.001]
  • [Cites] Minerva Ginecol. 2007 Feb;59(1):43-9 [17353873.001]
  • [Cites] Fertil Steril. 2007 Jul;88(1):1-17 [17493618.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Oct;8(10):821-9 [17907058.001]
  • [Cites] Clin Interv Aging. 2007;2(4):567-76 [18225457.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):236-41 [18434134.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):197-206 [18508261.001]
  • [Cites] Urology. 2008 Aug;72(2):247-54 [18502483.001]
  • [Cites] Curr Opin Chem Biol. 2008 Aug;12(4):418-26 [18662801.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):3691-6 [18697867.001]
  • [Cites] Cell. 2000 Jul 7;102(1):109-26 [10929718.001]
  • (PMID = 19846549.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anabolic Agents; 0 / Androgens; 0 / Antigens, Viral, Tumor; 0 / Receptors, Androgen; 0 / Testosterone Congeners; 0 / Viral Core Proteins; 0 / p27 antigen, Mouse mammary tumor virus
  • [Other-IDs] NLM/ PMC2794752
  •  go-up   go-down


Advertisement
4. Surguladze D, Deevi D, Claros N, Corcoran E, Wang S, Plym MJ, Wu Y, Doody J, Mauro DJ, Witte L, Busam KJ, Pytowski B, Rodeck U, Tonra JR: Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res; 2009 Jul 15;69(14):5643-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.
  • Cancer patients receiving epidermal growth factor receptor (EGFR) antibody therapy often experience an acneiform rash of uncertain etiology in skin regions rich in pilosebaceous units.
  • This effect was preceded by the appearance of lipid-filled hair follicle distensions adjacent to enlarged sebaceous glands.
  • The cytokine tumor necrosis factor-alpha (TNFalpha), localized immunohistochemically to this affected region of the pilosebaceous unit, was specifically up-regulated by ME1 in skin but not in other tissues examined.
  • Moreover, skin inflammation was reduced by cotreatment with the TNFalpha signaling inhibitor, etanercept, indicating the involvement of TNFalpha in this inflammatory process.
  • Our results provide a mechanistic framework to develop evidence-based trials for EGFR antibody-induced skin rash in patients with cancer.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Dermatitis / prevention & control. Interleukin-1 / antagonists & inhibitors. Receptor, Epidermal Growth Factor / immunology. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Animals. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Disease Models, Animal. Enzyme-Linked Immunosorbent Assay. Etanercept. Exanthema / chemically induced. Exanthema / prevention & control. Female. Humans. Immunoglobulin G / pharmacology. Interleukin 1 Receptor Antagonist Protein / pharmacology. Mice. Mice, SCID. Receptors, Tumor Necrosis Factor. Reverse Transcriptase Polymerase Chain Reaction. Skin / drug effects. Skin / metabolism. Skin / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Etanercept .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19584274.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antibodies, Monoclonal; 0 / Immunoglobulin G; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Interleukin-1; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; OP401G7OJC / Etanercept
  •  go-up   go-down


5. Murthy R, Honavar SG, Burman S, Vemuganti GK, Naik MN, Reddy VA: Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. Ophthal Plast Reconstr Surg; 2005 Jul;21(4):307-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis.
  • A 55-year-old Asian Indian woman who had recurrent sebaceous gland carcinoma of the left lower eyelid with orbital extension and regional lymph node metastasis was treated with neoadjuvant chemotherapy, using a combination of carboplatin and 5-fluorouracil.
  • Eyelid-sparing orbital exenteration was performed after 3 cycles of chemotherapy, followed by radiotherapy to the regional lymph nodes.
  • Subsequently, 3 cycles of adjuvant chemotherapy were administered.
  • Significant eyelid and orbital tumor volume reduction was achieved with neoadjuvant chemotherapy, making eyelid-sparing orbital exenteration possible.
  • Chemotherapy also spared the patient from radical neck dissection.
  • The patient had limited morbidity and was free of local, regional, and systemic disease at 26 months of follow-up.
  • [MeSH-major] Adenocarcinoma, Sebaceous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Eyelid Neoplasms / drug therapy. Orbital Neoplasms / drug therapy. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052148.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Sheikh SS, Amr SS: Mycotic cysts: report of 21 cases including eight pheomycotic cysts from Saudi Arabia. Int J Dermatol; 2007 Apr;46(4):388-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These fungi gain access to the tissues via a wooden splinter or thorn.
  • No deep tissue involvement or extension to bone is known to occur.
  • All cases with the diagnosis of cysts with fungi, thorns, or splinters and associated granulomatous and acute inflammation were reviewed.
  • No extension to deep tissues was noted.
  • The clinical impression varied widely including ganglion, sebaceous cyst, giant cell tumor of the tendon sheath, and lipoma.
  • No antifungal chemotherapy was needed or administered in any of the patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442079.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Shields CL, Naseripour M, Shields JA, Eagle RC Jr: Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology; 2002 Nov;109(11):2129-33
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma.
  • PURPOSE: To evaluate the efficacy of topical mitomycin-C for pagetoid invasion of the conjunctiva by sebaceous gland carcinoma.
  • INTERVENTION: All patients received topical 0.04% mitomycin-C four times daily for 1 week followed by 1 week off medication.
  • The treatment cycles were repeated until resolution of the conjunctival malignancy was clinically evident.
  • PARTICIPANTS: Four patients with histopathologically proven intraepithelial (pagetoid) invasion of the conjunctiva by sebaceous gland carcinoma were managed with this regimen.
  • Before treatment, the main tumor site included the upper eyelid in two cases and the lower eyelid in two cases.
  • Previous resection of the tumor had been performed elsewhere in three cases over the prior 6 years.
  • At the time of our examination, map biopsies confirmed pagetoid invasion involving 25% to 90% of the conjunctival surface, with bulbar, forniceal, and tarsal conjunctival involvement in all four cases and corneal extension in one case.
  • There was no evidence of deep tumor within the conjunctival stroma or tarsus in any case.
  • After treatment, medication intolerance and early discontinuation occurred in one patient, and continued tumor progression was documented.
  • Of the remaining three patients, chemotherapy was used for a mean of four cycles with complete resolution of the pagetoid invasion, confirmed histopathologically in two cases, and without recurrence in all three cases over 12 months (mean) follow-up.
  • The medication caused moderate temporary local irritation but no serious intraocular or extraocular complications.
  • CONCLUSIONS: Preliminary evidence suggests that topical mitomycin-C is effective treatment for pagetoid invasion of the conjunctiva by sebaceous gland carcinoma.
  • Longer follow-up is necessary to assess the duration of tumor control.
  • [MeSH-major] Adenocarcinoma, Sebaceous / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Conjunctival Neoplasms / drug therapy. Eyelid Neoplasms / drug therapy. Mitomycin / therapeutic use. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Female. Humans. Male. Neoplasm Invasiveness. Prospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12414427.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


8. Husain A, Blumenschein G, Esmaeli B: Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol; 2008 Mar;47(3):276-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid.
  • OBJECTIVE: To report the management and outcomes in patients with metastatic eyelid sebaceous cell carcinoma.
  • METHODS: The clinical records of four patients with metastatic eyelid sebaceous cell carcinoma treated between January 1999 and August 2006 were reviewed.
  • Time from diagnosis of eyelid carcinoma to metastasis ranged from 0 to 62 months.
  • Treatment of regional nodal metastasis consisted of complete neck dissection followed by radiation therapy.
  • One patient developed lung metastasis 5 years after the diagnosis of eyelid tumor; she was treated with systemic chemotherapy followed by subtotal lung resection.
  • Systemic chemotherapy was considered for two additional patients: in one, chemotherapy was deferred due to poor performance status and ongoing medical problems; and another patient died before chemotherapy could be started.
  • The patient with bony metastasis was treated with radiation therapy to the spine.
  • The follow-up time from diagnosis of metastasis to last contact or death ranged from 1 month to 3 years (median of 21 months).
  • CONCLUSION: Eyelid sebaceous cell carcinoma can result in systemic metastasis and death.
  • Metastasis can be discovered as late as 5 years after treatment of the eyelid carcinoma, warranting continued surveillance.
  • Treatment of metastatic disease may include a combination of chemotherapy, radiation, and surgical neck dissection.
  • [MeSH-major] Adenocarcinoma, Sebaceous / secondary. Bone Neoplasms / secondary. Eyelid Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Parotid Neoplasms / secondary. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Chalazion / diagnosis. Diagnostic Errors. Female. Humans. Lymphatic Metastasis / radiotherapy. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289332.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Duman DG, Ceyhan BB, Celikel T, Ahiskali R, Duman D: Extraorbital sebaceous carcinoma with rapidly developing visceral metastases. Dermatol Surg; 2003 Sep;29(9):987-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraorbital sebaceous carcinoma with rapidly developing visceral metastases.
  • BACKGROUND: Extraorbital sebaceous carcinoma (SC) is a rare carcinoma of the skin but is known to have a good prognosis in terms of metastasis and survival.
  • RESULTS: Local excision of the primary cutaneous tumor with negative margins did not prevent the rapid and fatal internal organ metastases.
  • The patient did not benefit from the docetaxel chemotherapy regimen applied after the distant metastases were developed.
  • [MeSH-major] Neoplasm Recurrence, Local. Neoplasms, Glandular and Epithelial / pathology. Paclitaxel / analogs & derivatives. Sebaceous Gland Neoplasms / pathology. Taxoids
  • [MeSH-minor] Aged. Antineoplastic Agents, Phytogenic / therapeutic use. Fatal Outcome. Female. Humans. Neoplasm Metastasis. Orbit. Viscera

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12930349.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Babilas P, Szeimies RM: The use of photodynamic therapy in dermatology. G Ital Dermatol Venereol; 2010 Oct;145(5):613-30
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of photodynamic therapy in dermatology.
  • In dermatology, topical photodynamic therapy (PDT) is a well established treatment modality which has mainly shown to be effective for dermato-oncologic conditions like actinic keratosis, Bowen's disease, in-situ squamous cell carcinoma and superficial basal cell carcinoma.
  • However, a therapeutical benefit of PDT is also evident for inflammatory dermatoses like localized scleroderma, acne vulgaris and granuloma annulare as well as for aesthetic indications like photo aged skin or sebaceous gland hyperplasia.
  • These drugs do not induce strong generalized cutaneous photosensitization like the systemically applied porphyrins or their derivatives.
  • Depending on the applied light dose and the concentration of the photosensitizer either cytotoxic effects resulting in tumor destruction or immunomodulatory effects improving the inflammatory conditions occur.
  • Treating superficial oncologic lesions (tumor thickness < 2-3 mm) cure rates achieved by PDT are equal to the cure rates of the respective standard therapeutic procedure.
  • The benefits of PDT are the low level of invasiveness and the excellent cosmetic results after treatment.
  • [MeSH-major] Photochemotherapy. Skin Diseases / drug therapy
  • [MeSH-minor] Acne Vulgaris / drug therapy. Carcinoma, Basal Cell / drug therapy. Cosmetic Techniques. Humans. Keratosis, Actinic / drug therapy. Light. Photosensitizing Agents / therapeutic use. Psoriasis / drug therapy. Skin Neoplasms / drug therapy. Warts / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20930696.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


11. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Stefanyszyn M, Shields CL: Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture. Ophthal Plast Reconstr Surg; 2005 Mar;21(2):92-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture.
  • PURPOSE: To determine incidence and distribution of conjunctival epithelial involvement by eyelid sebaceous carcinoma and to make recommendations regarding its management.
  • METHODS: The medical records were reviewed retrospectively on patients with histopathologically confirmed sebaceous carcinoma of the eyelids managed at the Oncology Service at Wills Eye Hospital.
  • The incidence of metastasis and tumor-related mortality was determined.
  • Based on these findings and personal surgical experience, recommendations are made regarding management of eyelid sebaceous carcinoma with involvement of the conjunctival epithelium.
  • RESULTS: Of 60 patients with sebaceous carcinoma, epithelial involvement of the conjunctiva was identified in 28 (47%).
  • Of the 28 cases, the neoplasm affected the following sites: superior tarsal and fornical conjunctiva in 28 (100%), inferior tarsal conjunctiva in 19 (68%), inferior fornical conjunctiva in 18 (64%), superior bulbar conjunctiva in 19 (68%), and inferior bulbar conjunctiva in 16 (57%).
  • Map biopsies, combined with cryotherapy, topical chemotherapy, local surgical resection, and orbital exenteration, were used to achieve local control.
  • CONCLUSIONS: Eyelid sebaceous carcinoma was found to exhibit epithelial involvement of the conjunctiva in 47% of cases, predominantly in the superior tarsal and fornical conjunctiva and less often in the inferior tarsal conjunctiva, caruncle, and cornea.
  • Treatment of this condition is challenging, and map biopsy, cryotherapy, topical chemotherapy, and newer surgical methods are being used more often by our group.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Carcinoma in Situ / pathology. Conjunctival Neoplasms / pathology. Eyelid Neoplasms / pathology. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cryotherapy. Humans. Incidence. Ophthalmologic Surgical Procedures. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15778660.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Lectures; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Dhall G, Ginsburg HB, Bodenstein L, Fefferman NR, Greco MA, Chang MW, Gardner S: Thymoma in children: report of two cases and review of literature. J Pediatr Hematol Oncol; 2004 Oct;26(10):681-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymoma is an uncommon tumor of childhood.
  • Stage of the tumor is an independent prognostic factor for survival.
  • Surgery is the treatment of choice for stage I and stage II tumors.
  • Chemotherapy is reserved for patients with refractory or metastatic disease.
  • However, radiation therapy is not an attractive option for children due to its side-effects on developing organs.
  • Both patients remain free of disease 3 years after surgery.
  • One of the patients also has nevus sebaceous.
  • The authors also discuss the possible association between the two disease entities.
  • [MeSH-major] Thymectomy. Thymoma / surgery. Thymus Neoplasms / surgery
  • [MeSH-minor] Adolescent. Cell Transformation, Neoplastic. Child. Chromosome Disorders / complications. Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 6. Dyspnea / etiology. Epithelial Cells / pathology. Female. Hamartoma / complications. Humans. Intellectual Disability / complications. Male. Neoplasm Staging. Remission Induction. Skin Diseases / complications. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15454843.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


13. Cauchi C, Visca P, Donati P, Lopez M: [Skin adnexal tumors]. Clin Ter; 2006 Jul-Aug;157(4):363-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin adnexal tumors].
  • Adnexal skin tumors are rare neoplasms that develop from hair follicles, sebaceous glands and sweat glands.
  • The diagnosis in always histologic and often it is sufficient to report the lesion simply as benign or malignant.
  • Radical surgery is the treatment of choice.
  • When the tumor is large, the Mohs technique can be used.
  • Etastatic disease, although rare, has a poor prognosis.
  • Chemotherapy and radiotherapy experience is very limited.
  • Overall, combination chemotherapy seems to be superior to single agent treatment.
  • [MeSH-major] Neoplasms, Adnexal and Skin Appendage / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17051975.001).
  • [ISSN] 0009-9074
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 104
  •  go-up   go-down


14. Oshiro H, Iwai T, Hirota M, Mitsudo K, Tohnai I, Minamimoto R, Omura-Minamisawa M, Nagashima Y, Yamanaka S, Fukui T, Kanazawa M, Sagawa H, Mita K, Nakayama T, Inayama Y: Primary sebaceous carcinoma of the tongue. Med Mol Morphol; 2010 Dec;43(4):246-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sebaceous carcinoma of the tongue.
  • Sebaceous carcinoma is the rarest type of oral malignancies.
  • We report a case of primary sebaceous carcinoma of the tongue.
  • Systemic imaging studies revealed that the patient had a T2N2cM0 (International Union Against Cancer guidelines) primary lingual tumor.
  • Superselective intraarterial chemotherapy was administered via the superficial temporal artery concurrent with daily radiotherapy.
  • Our case demonstrates that superselective intraarterial chemotherapy combined with concurrent radiotherapy can be effective in treating the primary lesion of patients with a sebaceous carcinoma of the tongue.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Tongue Neoplasms / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Lymphatic Metastasis. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1090-100 [18411003.001]
  • [Cites] Am J Dermatopathol. 1999 Oct;21(5):426-31 [10535570.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Jan;99(1):79-84 [15599352.001]
  • [Cites] J Laryngol Otol. 1996 May;110(5):500-2 [8762330.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2009 May;135(5):511-4 [19451474.001]
  • [Cites] Br J Oral Maxillofac Surg. 2003 Apr;41(2):84-7 [12694699.001]
  • [Cites] J Cutan Pathol. 2008 Jul;35(7):641-6 [18201230.001]
  • [Cites] Arch Ophthalmol. 1999 Jun;117(6):776-83 [10369589.001]
  • [Cites] Cancer. 2009 Jan 1;115(1):158-65 [18988294.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Jul;264(7):829-32 [17285332.001]
  • [Cites] Nagoya J Med Sci. 2006 Jun;68(3-4):101-8 [16967775.001]
  • [Cites] J Clin Pathol. 2006 Nov;59(11):1166-70 [16556662.001]
  • [Cites] J Cutan Pathol. 2008 Jan;35(1):40-5 [18095993.001]
  • [Cites] Br J Cancer. 2008 Mar 25;98(6):1039-45 [18283309.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Dec;72(6):709-11 [1812454.001]
  • [Cites] Eye (Lond). 1999;13 ( Pt 1):104-8 [10396393.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33(9):634-41 [16965339.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Jul;55(7):751-4 [9216510.001]
  • [Cites] Pathol Int. 2005 Mar;55(3):137-43 [15743322.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1953 Sep;6(9):1072-7 [13088005.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Aug;26(4):293-4 [9258724.001]
  • [Cites] Ophthalmologica. 2007;221(5):331-9 [17728556.001]
  • [Cites] Pathol Int. 2008 Aug;58(8):483-8 [18705767.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1428-35 [20605340.001]
  • (PMID = 21267703.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Poothullil AM, Colby KA: Topical medical therapies for ocular surface tumors. Semin Ophthalmol; 2006 Jul-Sep;21(3):161-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical medical therapies for ocular surface tumors.
  • We review the use of three topical medications for the therapy of ocular surface tumors: mitomycin C, 5-fluorouracil, and interferon alpha-2B.
  • Topical agents were used as both primary and adjuvant therapy.
  • Rates of tumor regression for CIN and squamous cell carcinoma ranged from 80 to 96%, and 70% of pigmented tumors regressed after an average follow-up of 27 months.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Lymphoma / drug therapy. Lymphoma / pathology. Mitomycin / administration & dosage. Mitomycin / adverse effects. Recombinant Proteins. Sebaceous Gland Neoplasms / drug therapy. Sebaceous Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912014.001).
  • [ISSN] 0882-0538
  • [Journal-full-title] Seminars in ophthalmology
  • [ISO-abbreviation] Semin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b; U3P01618RT / Fluorouracil
  • [Number-of-references] 52
  •  go-up   go-down


16. Navarini AA, Trüeb RM: 3 cases of dissecting cellulitis of the scalp treated with adalimumab: control of inflammation within residual structural disease. Arch Dermatol; 2010 May;146(5):517-20
MedlinePlus Health Information. consumer health - Cellulitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3 cases of dissecting cellulitis of the scalp treated with adalimumab: control of inflammation within residual structural disease.
  • BACKGROUND: Dissecting cellulitis of the scalp (DCS) is a chronic inflammatory disease of scalp hair follicles manifesting as multiple painful nodules and abscesses that interconnect via sinus tracts.
  • The disease tends to run a progressive course that eventually results in scarring alopecia.
  • The condition is thought to represent a follicular occlusion disorder.
  • Sebaceous and keratinous material within dilated pilosebaceous units accumulates until follicles burst, with subsequent neutrophilic inflammatory reaction and abscess formation.
  • Treatment remains unsatisfactory.
  • While oral antibiotics, intralesional corticosteroids, isotretinoin, or dapsone are insufficient, in this case series the inflammation responsible for scarifying tissue destruction was directly targeted by means of the tumor necrosis factor antagonist adalimumab.
  • Observation Clinical signs of inflammation as well as burden of disease measured by a score of 0 to 10 (P < .04) was reduced rapidly by adalimumab.
  • Histopathologic characteristics demonstrated marked improvement of inflammation, despite persistence of underlying structural disease.
  • CONCLUSIONS: Adalimumab is effective for treatment of DCS.
  • Relapse on discontinuation of therapy can be expected depending on persisting structural disease.
  • Continuous treatment or combined surgical resection of involved areas could be necessary for definitive resolution of disease.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Cellulitis / drug therapy
  • [MeSH-minor] Adalimumab. Adult. Antibodies, Monoclonal, Humanized. Drug Delivery Systems. Humans. Inflammation / drug therapy. Inflammation / etiology. Inflammation / physiopathology. Male. Scalp / pathology. Secondary Prevention. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231491.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Tumor Necrosis Factor-alpha; FYS6T7F842 / Adalimumab
  •  go-up   go-down






Advertisement